Mondaq Canada: Intellectual Property
Borden Ladner Gervais LLP
The Federal Court recently issued the public decision in the reference on the patent infringement finding and the section 8 damages finding between AstraZeneca and Apotex.
Aitken Klee
In Les Marques Metro / Metro Brands S.E.N.C. v. 1161396 Ontario Inc., 2017 FC 806, Metro appealed a Trade-marks Opposition Board decision which allowed S&M Enterprises' registration...
Goldman Sloan Nash & Haber LLP
Name changes and rebrands are closely related to choosing a brand name.
Norton Rose Fulbright Canada LLP
The Federal Court recently granted the appeal of Les Marques Metro / Metro Brands SENC (Metro) of the Opposition Board decision dated December 22, 2015.
Borden Ladner Gervais LLP
The Federal Court of Appeal ("FCA") dismissed the appeal of a Federal Court's ("FC") decision dismissing Apotex's motion for partial summary judgment.
Norton Rose Fulbright Canada LLP
Ça y est, l'année scolaire bat son plein, et toutes sortes d'activités sont lancées pour financer les activités des élèves.
Torys LLP
On September 27, a two-member panel hearing of the PMPRB issued a rare excessive-pricing decision relating to the drug Soliris (eculizumab), manufactured by Alexion Pharmaceuticals Inc. (Alexion).
Bereskin & Parr LLP
Competitive technology and industry sector intelligence are critical aspects of maintaining and increasing marketing share for a technology company.
Deeth Williams Wall LLP
The FCA affirmed the FC's finding that the ‘191 Patent failed to sufficiently disclose how to synthesize the claimed compound.
Deeth Williams Wall LLP
The decision may be appealed to the Federal Court of Appeal within 30 days of the date of the decision.
Borden Ladner Gervais LLP
This is an application pursuant to the Patented Medicines (Notice of Compliance) Regulations.
Smart & Biggar/Fetherstonhaugh
In Canada, trademarks for pharmaceutical preparations and related products have faced numerous challenges, some of which are unique to the industry.
BOYNECLARKE LLP
This fall the Federal government will undertake a mandated review of the Copyright Act.
Bereskin & Parr LLP
Dans l'arrêt AstraZeneca Canada Inc. c. Apotex Inc. 2017 CSC 36, la Cour suprême a limité considérablement la capacité de contester le monopole d'un brevet au motif d'une promesse...
Smart & Biggar/Fetherstonhaugh
In its first decision to consider the Supreme Court of Canada's landmark decision in AstraZeneca Canada Inc v Apotex Inc, 2017 SCC 36 [Esomeprazole](see our article here) on the utility requirement, the Federal Court of Appeal has overturned a finding of inutility made under the promise doctrine, with practical guidance for the requirement of a scintilla of utility: Bristol-Myers Squibb v Apotex, 2017 FCA 190.
McMillan LLP
Dubbed the winner of the US Chamber of Commerce most ridiculous lawsuit of 2015 award, Naruto, et al. v David John Slater examined whether a monkey could have copyright in its selfie.
Borden Ladner Gervais LLP
The parties were allowed to make post-hearing submissions as to the impact of the Supreme Court's decision on the present appeal.
Miller Thomson LLP
Most of the Canada-European Union Comprehensive Economic and Trade Agreement Implementation Act (CETA Implementation Act) came into force on September 21, 2017.
Fasken Martineau
The Comprehensive Economic and Trade Agreement (CETA) was signed by Canada and the European Union (EU) on October 30, 2016.
Gowling WLG
In view of the UK Supreme Court's judgment in Actavis v Eli Lilly, when will an 'equivalent' infringe as an immaterial variant?
Latest Video
Most Popular Recent Articles
Blaney McMurtry LLP
Below are the summaries of this week's civil decisions of the Court of Appeal for Ontario.
Deeth Williams Wall LLP
The FCA affirmed the FC's finding that the ‘191 Patent failed to sufficiently disclose how to synthesize the claimed compound.
Blake, Cassels & Graydon LLP
CETA is the Comprehensive Economic and Trade Agreement between Canada and the European Union (EU) and its member states.
Deeth Williams Wall LLP
The decision may be appealed to the Federal Court of Appeal within 30 days of the date of the decision.
Goldman Sloan Nash & Haber LLP
Recent decisions of the Federal Court of Appeal and the Ontario Superior Court of Justice raise some concerns about the interaction between IP rights and the Competition Act.
McCarthy Tétrault LLP
In AstraZeneca v Apotex, 2017 FC 726, the Federal Court issued its damages decision concerning Apotex's infringement of a patent pertaining to AstraZeneca's LOSEC (omeprazole) drug.
Norton Rose Fulbright Canada LLP
When negotiating an M&A deal involving a technology company, parties need to pay particular importance to the representations and warranties regarding the target company's intellectual property (IP).
Aitken Klee
On September 18, 2017, the Federal Court of Appeal released its decision in BMS' appeal of a decision dismissing its prohibition application in respect of dasatinib and Canadian Patent Nos. 2,366,932 and 2,519,898.
Fasken Martineau
The Board considers and certifies tariff proposals that are filed by the different collective societies that represent copyright owners.
Goldman Sloan Nash & Haber LLP
A recent decision of the English Court of Appeal considered a defence alleging informative use of a third party's trademark.
Article Search Using Filters
Related Topics
Mondaq Advice Centre (MACs)
Popular Authors
Popular Contributors
Up-coming Events Search
Tools
Font Size:
Translation
Channels
Mondaq on Twitter
Partners
In association with